ValuEngine Lowers Fresenius Medical Care AG & Co. (NYSE:FMS) to Sell

ValuEngine lowered shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a hold rating to a sell rating in a report issued on Tuesday morning, ValuEngine reports.

A number of other equities research analysts also recently issued reports on the stock. Morgan Stanley downgraded shares of Fresenius Medical Care AG & Co. from an equal weight rating to an underweight rating in a research report on Friday, December 6th. DZ Bank restated a neutral rating on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, October 30th. Redburn Partners restated a neutral rating on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. restated a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Thursday, August 29th. Finally, Royal Bank of Canada restated a neutral rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, August 19th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $45.81.

FMS stock opened at $36.72 on Tuesday. The firm has a 50 day moving average of $36.22 and a 200-day moving average of $35.84. Fresenius Medical Care AG & Co. has a 12-month low of $30.99 and a 12-month high of $42.75. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 0.75. The company has a market cap of $21.89 billion, a price-to-earnings ratio of 16.18, a PEG ratio of 3.60 and a beta of 1.46.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.08. Fresenius Medical Care AG & Co. had a net margin of 7.47% and a return on equity of 9.92%. The company had revenue of $4.91 billion during the quarter, compared to the consensus estimate of $4.72 billion. Sell-side analysts forecast that Fresenius Medical Care AG & Co. will post 2.44 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of FMS. Morgan Stanley raised its position in shares of Fresenius Medical Care AG & Co. by 53.3% during the 2nd quarter. Morgan Stanley now owns 1,850,796 shares of the company’s stock worth $72,700,000 after purchasing an additional 643,494 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Fresenius Medical Care AG & Co. by 1,174.5% during the 3rd quarter. SG Americas Securities LLC now owns 377,848 shares of the company’s stock worth $12,692,000 after purchasing an additional 348,201 shares during the last quarter. Marshall Wace North America L.P. raised its position in shares of Fresenius Medical Care AG & Co. by 25.1% during the 2nd quarter. Marshall Wace North America L.P. now owns 159,652 shares of the company’s stock worth $6,271,000 after purchasing an additional 32,016 shares during the last quarter. Silvercrest Asset Management Group LLC acquired a new position in shares of Fresenius Medical Care AG & Co. during the 2nd quarter worth approximately $1,095,000. Finally, Renaissance Technologies LLC raised its position in shares of Fresenius Medical Care AG & Co. by 87.9% during the 2nd quarter. Renaissance Technologies LLC now owns 52,600 shares of the company’s stock worth $2,066,000 after purchasing an additional 24,600 shares during the last quarter. Hedge funds and other institutional investors own 1.40% of the company’s stock.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Further Reading: What are the reasons investors use put options?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.